Who is sponsoring NCT00177684?

NCT00177684 is sponsored by University of Pittsburgh.

What condition does NCT00177684 study?

NCT00177684 studies Lung Transplantation, Fungal Infections.

What is the status of NCT00177684?

NCT00177684 is currently COMPLETED.

Last reviewed 2008-12-16 · How we verify

Pharmacokinetic Profiles of Inhaled Lipid Complex Amphotericin B (Abelcet ®)

NCT00177684 Phase 3 COMPLETED

The purpose of this study is to determine the optimal delivery system for the nebulization of the lipid complex amphotericin B (Abelcet ®) in lung transplant recipients who are positive for invasive aspergillosis (IA) in their lungs. Additionally, the investigators hope to determine the concentrations of amphotericin B achieved in the epithelial lining fluid, and serum with the administration of four days of lipid complex of amphotericin B (Abelcet ®) (QD) via aerosolized nebulization

Details

Lead sponsor	University of Pittsburgh
Phase	Phase 3
Status	COMPLETED
Enrolment	48
Start date	2004-09
Completion	2005-09

Conditions

Lung Transplantation
Fungal Infections

Interventions

Amphotericin B

Primary outcomes

To determine the optimal delivery system for the nebulization of the lipid complex amphotericin B (Abelcet ®).

Countries

United States